What Is DPP4? Its Role in Diabetes and Overall Health

DPP4, short for dipeptidyl peptidase-4, is an enzyme that sits on cell surfaces throughout the body and also circulates freely in the bloodstream. Its best-known job is chopping up gut hormones called incretins, which help regulate blood sugar after meals. That single function made DPP4 a blockbuster drug target for type 2 diabetes, but the enzyme does far more than manage glucose. It influences immune-cell signaling, fat metabolism, kidney function, and even serves as the entry point for certain coronaviruses, making it one of the more versatile and medically interesting proteins in human biology.

How DPP4 Works at the Molecular Level

DPP4 is a serine protease, meaning it cuts other proteins at specific locations. It snips peptides that have the amino acid alanine or proline sitting in the second position of their chain. Both the version anchored to cell membranes and the soluble version floating in plasma carry out this cutting activity.¹ Sometimes that cleavage simply deactivates a peptide. Other times it produces entirely new fragments with their own biological effects, which can either complement or compete with the original molecule’s actions.

The two incretins that matter most for blood sugar control are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). After you eat, your gut releases both hormones to tell your pancreas to produce insulin. DPP4 rapidly chews them up. It clips two amino acids off the front of GLP-1, producing fragments with roughly a hundredfold less ability to activate the GLP-1 receptor. GIP gets a similar treatment, yielding a fragment that cannot activate its own receptor and, at high concentrations, may even weakly block it.¹ This rapid degradation is why the natural lifespan of active GLP-1 in your bloodstream is only a couple of minutes.

Where DPP4 Shows Up in the Body

DPP4 is not confined to the gut or the pancreas. It appears on fibroblasts, immune cells, kidney tubules, liver cells, and the surface of fat cells, among others.² In the kidney, DPP4 is concentrated in the glomeruli and the proximal tubule segments, where it helps regulate sodium transport and processes cleaved peptide fragments for absorption.³

The soluble form of DPP4 deserves special attention. Adipose tissue, particularly visceral fat, is a major source of circulating DPP4, making it qualify as an adipokine, a signaling molecule secreted by fat. Soluble DPP4 released by mature fat cells can interfere with insulin signaling both locally and in distant tissues and promotes a pro-inflammatory environment.⁴ This connection between visceral fat, circulating DPP4, and insulin resistance helps explain why the enzyme’s activity tends to climb in people with obesity and metabolic syndrome.

DPP4 Inhibitors as Diabetes Medications

If DPP4 destroys the incretins that stimulate insulin release, blocking DPP4 should keep those incretins active longer and improve blood sugar control. That logic led to the development of a drug class called DPP4 inhibitors, sometimes marketed under names like sitagliptin, saxagliptin, linagliptin, alogliptin, and vildagliptin. They are oral pills, taken once daily, that suppress DPP4 enzymatic activity by 80% or more throughout the day.

Clinical trials confirm they work. In one 28-day trial of linagliptin, active GLP-1 levels rose significantly, fasting blood sugar dropped, and hemoglobin A1c fell compared to placebo. Glucagon, a hormone that raises blood sugar, also decreased starting on the very first day of treatment.⁵ Because the insulin-boosting effect is glucose-dependent, meaning the drug mainly works when blood sugar is elevated, the risk of dangerously low blood sugar is low. That risk rises, though, if a DPP4 inhibitor is combined with a sulfonylurea, a different class of diabetes drug that pushes insulin release regardless of glucose levels.⁶

How DPP4 Inhibitors Compare to GLP-1 Receptor Agonists

Both DPP4 inhibitors and GLP-1 receptor agonists tap into the same incretin pathway, but they do it differently. DPP4 inhibitors preserve whatever GLP-1 your gut naturally produces. GLP-1 receptor agonists flood the system with synthetic versions of GLP-1 (or closely related molecules) at much higher concentrations. The practical result is that GLP-1 receptor agonists tend to lower blood sugar more, produce weight loss of around one to three kilograms over six to seven months, and show greater patient-reported treatment satisfaction, while DPP4 inhibitors are generally weight-neutral.⁶

Head-to-head comparisons in randomized trials have also shown GLP-1 receptor agonists outperforming DPP4 inhibitors on beta-cell function, cardiac function, and urinary albumin levels.⁷ The trade-off is convenience and side effects: DPP4 inhibitors are pills with relatively few gastrointestinal complaints, while most GLP-1 receptor agonists require injection and commonly cause nausea, especially at the start of treatment.

Cardiovascular Safety

After a separate diabetes drug was pulled from the market over heart risks years ago, regulators began requiring large cardiovascular outcome trials for new glucose-lowering drugs. Several such trials have been completed for DPP4 inhibitors, and the overall picture is reassuring but not exciting. A meta-analysis pooling data from multiple trials found that DPP4 inhibitors did not significantly raise or lower the risk of heart attack, stroke, cardiovascular death, or hospitalization for unstable angina compared to placebo.⁸ A separate meta-analysis confirmed the neutral picture for individual atherothrombotic events, with relative risks hovering close to 1.0 across categories.⁹

One wrinkle appeared with saxagliptin. The SAVOR-TIMI 53 trial reported a roughly 27% increase in hospitalization for heart failure in patients taking that particular DPP4 inhibitor.¹⁰ Other DPP4 inhibitors have not consistently reproduced this signal, and when all are pooled together the overall risk for heart failure hospitalization remains statistically non-significant. Still, the finding has made clinicians cautious about prescribing saxagliptin to patients already at high risk for heart failure. DPP4 inhibitors are sometimes described as cardiovascularly “safe but boring” compared to GLP-1 receptor agonists, which have demonstrated actual cardiovascular benefits in their own outcome trials.

DPP4 and the Immune System

DPP4 also goes by the name CD26, a designation it earned because immunologists identified it on the surface of T cells before its enzymatic role was well understood. On immune cells, DPP4 does more than trim peptides. It acts as a co-stimulatory molecule, helping to activate T cells directly by triggering an internal signaling cascade that leads to NF-κB activation and cell proliferation. It also physically connects T cells to antigen-presenting cells through an interaction with a protein called caveolin-1, which strengthens the bond needed for an effective immune response.¹¹

This dual identity raises a practical question: do DPP4 inhibitor drugs dampen the immune system? So far, the large clinical trials have not shown a meaningful increase in infections or immune-related problems with standard diabetes doses. But the immune connection is why researchers keep watching DPP4 carefully in contexts beyond diabetes, including autoimmune conditions and transplant medicine.

Kidney and Liver Health

DPP4 activity is high in the kidney, and there is growing interest in whether inhibiting it can slow the progression of diabetic kidney disease. Clinical and experimental studies suggest that DPP4 inhibitors have beneficial effects on the diabetic kidney that go beyond simple glucose control, reducing inflammation, fibrosis, and oxidative damage.¹² One large trial found a reduction in proteinuria, a marker of kidney damage, in patients with early-to-moderate chronic kidney disease taking a DPP4 inhibitor.³ These kidney-protective effects may stem partly from the enzyme’s non-incretin substrates, since DPP4 also cleaves peptides involved in blood vessel regulation and inflammatory signaling within the kidney itself.¹³

In the liver, a similar pattern appears. People with fatty liver disease (steatohepatitis) tend to have elevated DPP4 levels in both liver tissue and blood. Those levels correlate with the severity of fat buildup, fibrosis, and liver cell death. In animal models, genetically deleting DPP4 improves insulin sensitivity and liver function.¹⁴ Whether DPP4 inhibitor pills meaningfully reverse human fatty liver disease remains an open question, but the biological plausibility is strong enough to justify ongoing clinical research.

Brain Health and Cognitive Function

People with type 2 diabetes are at higher risk for cognitive decline, and researchers have explored whether DPP4 inhibitors might help protect the brain. A meta-analysis found that DPP4 inhibitor use significantly reduced the rate of cognitive impairment in people with type 2 diabetes, alongside improvements in fasting blood sugar and A1c.¹⁵ Whether the brain benefit comes purely from better blood sugar control or from some direct neuroprotective effect is still debated.

Laboratory studies suggest a more direct mechanism may be at play. In experimental models of Alzheimer’s disease, DPP4 inhibitors have been shown to reduce the buildup of amyloid-beta plaques, decrease tau protein abnormalities, and lower neuroinflammation and oxidative stress in the brain.¹⁶ These are early-stage findings, and nobody is prescribing DPP4 inhibitors for dementia prevention. But the overlap between metabolic disease and neurodegeneration makes DPP4 one of the more interesting molecular crossroads in that research space.

DPP4 as a Viral Entry Point

In 2012, researchers identified DPP4 as the receptor that MERS-CoV, the coronavirus causing Middle East Respiratory Syndrome, uses to enter human cells. The spike protein on the virus surface binds directly to DPP4 on airway cells, and mutagenesis studies have pinpointed specific residues in DPP4 that are critical for viral attachment and cell entry.¹⁷ This is a separate function from DPP4’s enzymatic activity; the virus latches onto the protein’s structure rather than being affected by its cutting ability.

The concern extends beyond MERS-CoV itself. A MERS-like coronavirus found circulating in pangolins also uses human DPP4 as its receptor and can infect human cells, aided by a furin cleavage site not seen in related bat viruses.¹⁸ The fact that DPP4-targeting coronaviruses keep surfacing in different animal reservoirs is part of why pandemic preparedness researchers monitor this receptor family closely. An important caveat: there is no evidence that taking a DPP4 inhibitor drug makes you more or less susceptible to these viruses. The drugs block the enzyme’s catalytic site, not the structural region the virus binds to.

DPP4 in Cancer Biology

DPP4 expression has been studied across multiple cancer types, and the picture is complicated. In most cancers studied so far, higher DPP4 expression appears to promote tumor progression.¹⁹ In colorectal cancer specifically, DPP4 expression has been linked to cancer stem cell populations and worse survival outcomes.²⁰ However, the role of DPP4 varies by tumor type and the form of the protein involved, so blanket statements about it being “pro-cancer” are premature.

Whether DPP4 inhibitor diabetes drugs affect cancer risk in patients is a natural follow-up question. The large cardiovascular outcome trials, which followed tens of thousands of patients for years, have not flagged an increased cancer signal. But these trials were designed to track heart outcomes, not cancer, so the question is not definitively settled. Elevated circulating DPP4 activity has separately been proposed as a biomarker, a measurable indicator in blood that could flag disease risk. One study found that higher plasma DPP4 activity was independently associated with the presence of coronary artery disease, even in people without diabetes.²¹ Whether monitoring DPP4 levels could be useful for screening is an active area of investigation, not yet clinical practice.

Exercise, Diet, and DPP4 Levels

You do not need a prescription to lower your DPP4 activity. Exercise training combined with weight loss reduced circulating DPP4 by about 10% in adults with metabolic syndrome, and that drop was directly correlated with improved insulin sensitivity and increased fat burning.²² Aerobic exercise alone, and aerobic exercise combined with vitamin D supplementation, have both been shown to lower DPP4 levels and raise GLP-1 in people with type 2 diabetes.²³

The dietary angle is less straightforward. Cell culture and rodent experiments found that whey protein increased DPP4 gene expression in muscle cells, and feeding rats whey protein after exercise boosted DPP4 gene activity in muscle tissue. But in humans, plasma DPP4 activity did not change after acute whey protein intake, a short bout of vigorous running, or resistance exercise sessions.²⁴ The discrepancy likely reflects the difference between what happens inside a single muscle cell and what shows up in the bloodstream. The practical takeaway is that sustained aerobic exercise and weight loss are the lifestyle interventions with clear evidence for lowering circulating DPP4, while individual meals or single workouts probably do not move the needle in a meaningful way.

DPP4 Inhibitors and Bullous Pemphigoid

One uncommon but notable side effect linked to DPP4 inhibitors is bullous pemphigoid, an autoimmune blistering skin condition typically seen in older adults. Multiple studies have reported an association, and a ten-year prospective study found that vildagliptin in particular was significantly associated with increased risk of developing the condition.²⁵ Other DPP4 inhibitors have been implicated as well, though the strength of the association varies by specific drug.²⁶

The suspected mechanism ties back to DPP4’s immune role. Because DPP4 normally helps regulate T cell activation and immune tolerance, inhibiting it could, in susceptible individuals, tip the immune system toward attacking proteins at the junction between the skin’s outer and inner layers. The good news is that bullous pemphigoid linked to DPP4 inhibitors often improves or resolves after the drug is discontinued. Still, older patients who develop unexplained blistering while on one of these medications should mention the drug to their dermatologist. One meta-analysis of DPP4 inhibitor cardiovascular trials also flagged a safety signal for pancreatitis, a rare but serious inflammation of the pancreas that has been debated since this drug class was introduced.⁹

Why People Respond Differently to DPP4 Inhibitors

Not everyone with type 2 diabetes responds equally well to DPP4 inhibitors, and genetics appears to be part of the reason. A genome-wide study in a Taiwanese population identified dozens of genetic variants associated with how well patients responded to DPP4 inhibitor therapy. The strongest signal involved a variant near the gene PRKD1, which is involved in beta-cell function and cell survival. Other genes flagged were related to cellular processes like apoptosis, suggesting that the health and resilience of insulin-producing cells influence how much benefit a patient gets from keeping their incretins intact.²⁷

This kind of pharmacogenomic work is still early. No clinic is genotyping patients before prescribing sitagliptin. But it illustrates why two patients with similar A1c levels can have very different experiences on the same DPP4 inhibitor. In the broader picture, understanding these genetic influences could eventually help clinicians predict who will do well on a DPP4 inhibitor and who might be better served by a GLP-1 receptor agonist or another class entirely.

DPP4 Substrates Beyond the Incretins

One of the most underappreciated aspects of DPP4 is how many peptides it cleaves besides GLP-1 and GIP. The enzyme processes neuropeptide Y, peptide YY, stromal cell-derived factor 1-alpha, and others. When DPP4 is inhibited, those peptides stick around longer, and their effects become amplified. In cardiac and kidney cells taken from genetically hypertensive rats, the persistence of these peptides under DPP4 inhibition stimulated cell proliferation and collagen production.²⁸ These are laboratory findings, not clinical outcomes, but they highlight why the effects of DPP4 inhibitors are not limited to blood sugar. By preserving dozens of peptides simultaneously, the drugs have downstream consequences that researchers are still mapping out.

The evolutionary conservation of DPP4 across species underscores just how fundamental this enzyme is. Researchers have demonstrated high structural similarity between human DPP4 and its counterpart in fruit flies, with key catalytic residues preserved across hundreds of millions of years of evolution. Known human DPP4 inhibitors even produce measurable glucose-lowering effects in fly models.²⁹ When a protein is conserved that thoroughly across the animal kingdom, it usually means it does something too important for evolution to tinker with freely. For DPP4, that “something” clearly extends well beyond any single organ system or disease.

1
Endocrine Reviews. Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
2
Biomedicine & Pharmacotherapy. Insight into the role of DPP-4 in fibrotic wound healing
3
PubMed. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4
4
PubMed Central. Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
5
PubMed Central. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus
6
PubMed Central. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
7
JAMA Network Open. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
8
PubMed Central. Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
9
PubMed. Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials
10
PubMed Central. DPP4 inhibitors and cardiovascular outcomes: safety on heart failure
11
PubMed Central. Cut to the chase: a review of CD26/dipeptidyl peptidase‐4’s (DPP4) entanglement in the immune system
12
PubMed Central. Renoprotective Effects of DPP-4 Inhibitors
13
PubMed Central. Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
14
Endocrinology and Metabolism. DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
15
PubMed Central. Effects of DPP4 Inhibitors as Neuroprotective Drug on Cognitive Impairment in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review
16
PubMed Central. DPP-4 inhibitors: a promising therapeutic approach against Alzheimer’s disease
17
PubMed Central. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
18
PubMed Central. A bat MERS-like coronavirus circulates in pangolins and utilizes human DPP4 and host proteases for cell entry
19
PubMed. DPP4, a potential tumor biomarker, and tumor therapeutic target: review
20
Cell Reports. Tumor Suppression and Drug Resistance via TP53-Mediated Regulation of Ferroptosis in Colorectal Cancer
21
PLoS ONE. Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease
22
PubMed Central. Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome
23
PubMed Central. The Effects of Aerobic Exercises and 25(OH) D Supplementation on GLP1 and DPP4 Level in Type II Diabetic Patients
24
PubMed Central. The serine protease, dipeptidyl peptidase IV as a myokine: dietary protein and exercise mimetics as a stimulus for transcription and release
25
PubMed Central. The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
26
PubMed Central. The effect of dipeptidyl peptidase-4 inhibitor on incidence and clinical course in bullous pemphigoid patients in a tertiary medical center
27
PubMed Central. Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes
28
PubMed Central. Cardiovascular DPP4 Inhibition, NPY 1–36, PYY 1–36, SDF-1 α, and a Hypertensive Genetic Background Conspire to Augment Cell Proliferation and Collagen Production
29
PubMed Central. Drosophila as a Rapid Screening Model to Evaluate the Hypoglycemic Effects of Dipeptidyl Peptidase 4 (DPP4) Inhibitors: High Evolutionary Conservation of DPP4